Capivasertib
- Generic Name
- Capivasertib
- Brand Names
- Truqap
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN6O2
- CAS Number
- 1143532-39-1
- Unique Ingredient Identifier
- WFR23M21IE
- Background
Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT03801369
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT03742102
- Locations
- π¬π§
Research Site, Oxford, United Kingdom
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 288
- Registration Number
- NCT03660826
- Locations
- πΊπΈ
Case Western Reserve University, Cleveland, Ohio, United States
πΊπΈSutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
πΊπΈKaiser Permanente-Baldwin Park, Baldwin Park, California, United States
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Conditions
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 124
- Registration Number
- NCT02523014
- Locations
- πΊπΈ
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
πΊπΈHenry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
πΊπΈHenry Ford Saint John Hospital - Breast, Grosse Pointe Woods, Michigan, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- πΊπΈ
Alaska Women's Cancer Care, Anchorage, Alaska, United States
πΊπΈAnchorage Oncology Centre, Anchorage, Alaska, United States
πΊπΈKatmai Oncology Group, Anchorage, Alaska, United States
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
- Conditions
- Progesterone Receptor NegativeStage III Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7Triple-Negative Breast CarcinomaBRCA2 Mutation CarrierHigh Grade Ovarian Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaBRCA1 Mutation CarrierRecurrent Ovarian CarcinomaRecurrent Uterine Corpus Carcinoma
- Interventions
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 159
- Registration Number
- NCT02208375
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.